OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLC

July 28th 2022

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

July 27th 2022

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Dr. Kahl on the Current Unmet Needs in MCL

July 26th 2022

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

Dr. Ryan on the Investigation of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

July 26th 2022

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Hays on the Importance of Clinical Trials in CRC

July 26th 2022

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

Dr. Choueiri on the Use of Adjuvant Pembrolizumab in RCC

July 25th 2022

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Wise on Unmet Needs in the Standard of Care in Prostate Cancer

July 25th 2022

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC

July 25th 2022

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

July 25th 2022

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Women in Oncology: Leukemia Therapies in Humans, for Humans

July 24th 2022

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Women in Oncology: Finding Strength and Support in Community

July 24th 2022

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

July 22nd 2022

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL

July 22nd 2022

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Dr. D’Angelo on Emerging Therapies in DLBCL

July 21st 2022

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Dr. Porter on the 3-Year Follow-Up Data From the CheckMate-9LA Trial in NSCLC

July 21st 2022

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

Dr. Ready on the Practice Implications of Nivolumab/Ipilimumab in NSCLC

July 21st 2022

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

July 21st 2022

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.